Oncology Reviews最新文献

筛选
英文 中文
Comparative effects of exercise and nutritional interventions on muscle mass and body composition in adults with cancer: a systematic review and network meta-analysis of randomized controlled trials. 运动和营养干预对成年癌症患者肌肉质量和身体成分的比较影响:随机对照试验的系统回顾和网络荟萃分析。
IF 4
Oncology Reviews Pub Date : 2026-10-29 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1926991
Siqi Gao, Yanting Dong
{"title":"Comparative effects of exercise and nutritional interventions on muscle mass and body composition in adults with cancer: a systematic review and network meta-analysis of randomized controlled trials.","authors":"Siqi Gao, Yanting Dong","doi":"10.3389/or.2026.1926991","DOIUrl":"https://doi.org/10.3389/or.2026.1926991","url":null,"abstract":"<p><strong>Introduction: </strong>Loss of muscle mass and changes in body composition are common in adults with cancer. We compared exercise, nutritional, and combined strategies and assessed the certainty and clinical interpretability of the evidence.</p><p><strong>Methods: </strong>We searched PubMed, Embase, the Cochrane Library, and Web of Science through April 2026 for randomized controlled trials reporting appendicular skeletal muscle mass, skeletal muscle index, lean mass, body mass index, body weight, or fat mass. Eight nodes were evaluated: standard of care (SOC), active low-intensity control (ALC), resistance exercise (RE), multicomponent exercise (ME), nutrition-only intervention (NOI), exercise-nutrition intervention without resistance exercise as the primary component (ENI), resistance exercise plus nutrition-only intervention (RE + NOI), and comprehensive exercise-nutrition intervention incorporating resistance exercise (ENI + RE). Random-effects network meta-analysis produced mean differences (MDs) with 95% confidence intervals (CIs); certainty was assessed with GRADE/CINeMA.</p><p><strong>Results: </strong>Twenty-one trials and eight intervention nodes were included. Most network estimates were of low certainty. ME was associated with lower BMI than SOC (MD -3.53, 95% CI -7.01 to -0.04), but not with statistically significant differences in body weight or fat mass. ENI + RE was associated with lower lean mass than SOC (MD -6.72, 95% CI -12.43 to -1.02); this sparse, low-certainty estimate should not be interpreted as evidence that combined interventions are harmful or ineffective. No intervention showed a consistent advantage across muscle mass outcomes.</p><p><strong>Conclusion: </strong>Relative rankings did not establish clinical superiority. Sparse direct evidence, heterogeneous cancer and treatment contexts, varied intervention protocols and measurement methods, and low certainty limit inference. More standardized head-to-head trials are needed.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1926991"},"PeriodicalIF":4.0,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13755329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149409282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Narrative review of non-pharmacological interventions for chemotherapy-induced peripheral neuropathy: exercise, physical therapy, cryotherapy and acupuncture. 化疗引起的周围神经病变的非药物干预:运动,物理治疗,冷冻治疗和针灸。
IF 4
Oncology Reviews Pub Date : 2026-10-19 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1922088
Lingjun Li, Mingsi Fan, Li Ni, Jing Wang, Li Qiao
{"title":"Narrative review of non-pharmacological interventions for chemotherapy-induced peripheral neuropathy: exercise, physical therapy, cryotherapy and acupuncture.","authors":"Lingjun Li, Mingsi Fan, Li Ni, Jing Wang, Li Qiao","doi":"10.3389/or.2026.1922088","DOIUrl":"10.3389/or.2026.1922088","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Chemotherapy-induced peripheral neuropathy (CIPN) is a heterogeneous, treatment-limiting adverse event of cytotoxic chemotherapy that impairs sensory, motor, autonomic and balance function, and substantially reduces cancer patients' quality of life. Current pharmacotherapy options are limited: duloxetine is the only guideline-recommended agent for established painful CIPN, while no drugs are approved for primary prevention. Non-pharmacological interventions have emerged as promising adjunctive strategies, yet evidence strength varies widely across modalities and patient subgroups. This narrative review aimed to synthesize contemporary clinical evidence of non-pharmacological interventions for CIPN prevention, symptom treatment and functional rehabilitation, to deliver stratified, chemotherapy-specific clinical guidance and identify gaps for future research.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Method: &lt;/strong&gt;A narrative review design was adopted, without pre-registration or standardized systematic review screening protocols. Targeted manual literature retrieval was conducted across PubMed, Web of Science, CNKI and Wanfang Data for peer-reviewed human clinical studies published between January 2018 and March 2025. We focused on four core non-pharmacological modalities for CIPN: multimodal exercise therapy, physical therapy incorporating cryotherapy, acupuncture-based complementary therapies, and behavioral self-management interventions. High-certainty evidence was defined as consistent results from large multicenter randomized controlled trials and network meta-analyses; moderate/low-certainty evidence was derived from small single-center trials and observational studies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Cumulative stratified evidence demonstrates clear heterogeneity in intervention efficacy and clinical applicability. Multimodal supervised exercise and physical rehabilitation carry the most consistent high-certainty evidence for both primary CIPN prevention and functional recovery, with significant improvements in numbness, neuropathic pain, balance and muscle strength. Cryotherapy shows robust preventive efficacy exclusively in patients receiving taxane chemotherapy, with insufficient supportive data for platinum or vinca alkaloid regimens. Acupuncture, including warm needle acupuncture, TEAS and electroacupuncture, provides moderate-to-low certainty adjunctive relief for refractory established CIPN symptoms but is not recommended as first-line therapy. Behavioral interventions exert limited direct therapeutic effects on nerve injury, yet effectively improve symptom coping, treatment adherence and long-term self-management. All interventions exhibit favorable safety profiles with minimal severe adverse events when individualized to patient fitness, comorbidities and chemotherapy regimens.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Non-pharmacological interventions cannot be considered uniformly effective for all CIPN populations; evidence strengt","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1922088"},"PeriodicalIF":4.0,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chinese herbal medicine combined with conventional therapy for gastric precancerous lesions: a systematic review and meta-analysis. 中药联合常规疗法治疗胃癌前病变:系统回顾和荟萃分析。
IF 4
Oncology Reviews Pub Date : 2026-10-19 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1947905
Chang Feng, Jiamin Cao, Lu Zhan, Shujing Yi, Yuanqi Li, Fang Li, Run Yang, Yuantao Zhong, Xingen Jiang, Ruo Chen, Gaofei Feng
{"title":"Chinese herbal medicine combined with conventional therapy for gastric precancerous lesions: a systematic review and meta-analysis.","authors":"Chang Feng, Jiamin Cao, Lu Zhan, Shujing Yi, Yuanqi Li, Fang Li, Run Yang, Yuantao Zhong, Xingen Jiang, Ruo Chen, Gaofei Feng","doi":"10.3389/or.2026.1947905","DOIUrl":"10.3389/or.2026.1947905","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Chronic atrophic gastritis and gastric precancerous lesions are associated with increased gastric cancer risk. Chinese herbal medicine is widely used as an adjunct to conventional therapy, but the certainty and clinical interpretation of its effects remain unclear.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the efficacy and safety of Chinese herbal medicine added to the same conventional therapy for chronic atrophic gastritis and gastric precancerous lesions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Eight international and Chinese databases and three trial registries were searched from inception to 31 March 2026 and updated to 16 August 2026. Randomised controlled trials comparing Chinese herbal medicine plus the same conventional therapy with conventional therapy alone and reporting extractable pathological outcomes were included. Random-effects models used restricted maximum likelihood estimation and Hartung-Knapp inference. Additional sensitivity analyses examined clinically comparable histopathology, baseline balance based on auditable pretreatment data, and exclusion of high-risk-of-bias results. Risk of bias was assessed using RoB 2 and certainty using GRADE.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Sixty-nine randomised trials comprising 6,983 participants in eligible comparisons were included. Exploratory Broad end-of-treatment analyses favoured combined treatment for gastric mucosal atrophy (30 studies; SMD -1.63, 95% CI -2.03 to -1.24), intestinal metaplasia (29 studies; SMD -1.48, 95% CI -1.90 to -1.06), and dysplasia or intraepithelial neoplasia (21 studies; SMD -1.25, 95% CI -1.51 to -0.99). Heterogeneity was substantial (I&lt;sup&gt;2&lt;/sup&gt; 82.4%-92.7%); prediction intervals crossed the null for atrophy and intestinal metaplasia but not for dysplasia/intraepithelial neoplasia. Sensitivity analyses restricted to clinically comparable histopathological assessments included only three to four studies and were imprecise, with confidence intervals crossing the null. &lt;i&gt;Helicobacter pylori&lt;/i&gt; clearance/negative conversion among baseline-positive participants was higher with combined treatment (15 studies; RR 1.25, 95% CI 1.15-1.37), whereas the strict test-of-cure sensitivity was imprecise (3 studies; RR 1.19, 95% CI 0.91-1.56). There was no clear evidence of a difference in reported adverse events (14-study evidence set; RR-contributing studies = 12; RR 0.93, 95% CI 0.58-1.50), which should not be interpreted as evidence of equivalent safety. Certainty was low for all five principal outcomes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Chinese herbal medicine added to conventional therapy may be associated with lower short-term pathological scores on average, but the magnitude and clinical meaning of these effects remain uncertain because of trial limitations, marked heterogeneity, and imprecision in clinically comparable analyses. The findings do not establish durable histological regression or gastric cancer prevention, and the pool","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1947905"},"PeriodicalIF":4.0,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast cancer adaptation to oxygen stress: mechanisms of tumor survival, progression, and therapeutic resistance. 乳腺癌对氧应激的适应:肿瘤生存、进展和治疗抵抗的机制。
IF 4
Oncology Reviews Pub Date : 2026-10-16 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1959034
Emmanuel Ifeanyi Obeagu, Izuchukwu Hilary Edeoga
{"title":"Breast cancer adaptation to oxygen stress: mechanisms of tumor survival, progression, and therapeutic resistance.","authors":"Emmanuel Ifeanyi Obeagu, Izuchukwu Hilary Edeoga","doi":"10.3389/or.2026.1959034","DOIUrl":"https://doi.org/10.3389/or.2026.1959034","url":null,"abstract":"<p><p>Breast cancer cells encounter heterogeneous oxygen conditions arising from abnormal vasculature, impaired perfusion, rapid proliferation, and fluctuating blood flow. Adaptation to oxygen stress is increasingly recognized as a major driver of tumor progression and therapeutic resistance. This review integrates current evidence on the mechanisms through which breast cancer cells adapt to oxygen stress and identifies opportunities for precision therapeutic intervention. Oxygen stress activates hypoxia-inducible factors and interconnected signaling networks that coordinate metabolic reprogramming, mitochondrial adaptation, reactive oxygen species generation, and redox homeostasis. These responses are reinforced by autophagy, unfolded protein response, epithelial-mesenchymal plasticity, cancer stemness, extracellular-matrix remodeling, angiogenesis, and immune suppression. Together, these mechanisms sustain cellular survival, facilitate invasion and metastasis, and promote resistance to chemotherapy, radiotherapy, endocrine therapy, HER2-directed treatment, and other targeted approaches. Oxygen-stress responses vary across breast cancer subtypes, emphasizing the need for biologically informed therapeutic strategies. Potential precision approaches include targeting hypoxia signaling, glycolytic and mitochondrial dependencies, lactate metabolism, antioxidant systems, autophagy, proteostasis, hypoxia-activated pathways, and hypoxia-associated immune suppression. Integrating molecular biomarkers, metabolic profiling, spatial technologies, and functional imaging may improve identification of tumors with actionable oxygen-stress dependencies. Oxygen-stress adaptation represents an interconnected survival network rather than a single hypoxia pathway. Therapeutically exploiting tumor-specific adaptive dependencies, while accounting for subtype and spatial heterogeneity, may provide new opportunities to overcome treatment resistance and improve precision management of breast cancer.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1959034"},"PeriodicalIF":4.0,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13720365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing unmet clinical needs in treatment-resistant breast cancer: expanding the diagnostic-prognostic landscape through next-generation inflammatory signatures. 解决治疗难治性乳腺癌未满足的临床需求:通过下一代炎症特征扩大诊断预后前景。
IF 4
Oncology Reviews Pub Date : 2026-10-16 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1918787
Emmanuel Ifeanyi Obeagu
{"title":"Addressing unmet clinical needs in treatment-resistant breast cancer: expanding the diagnostic-prognostic landscape through next-generation inflammatory signatures.","authors":"Emmanuel Ifeanyi Obeagu","doi":"10.3389/or.2026.1918787","DOIUrl":"10.3389/or.2026.1918787","url":null,"abstract":"<p><p>Treatment-resistant breast cancer remains a major clinical challenge because conventional clinicopathological and molecular biomarkers incompletely capture the dynamic interactions between tumour cells, immunity, inflammation, and the systemic host response. Next-generation inflammatory signatures offer an opportunity to expand the diagnostic-prognostic landscape by integrating cellular, molecular, immune, and thromboinflammatory indicators with established tumour characteristics. This narrative review critically examines emerging evidence for neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, C-reactive protein, cytokines, tumour-associated macrophages, myeloid-derived suppressor cells, neutrophil extracellular traps, coagulation biomarkers, and liquid-biopsy-derived measures in treatment-resistant breast cancer. Particular attention is given to sources of heterogeneity, including population characteristics, tumour subtype, treatment exposure, comorbid inflammation, sampling time, specimen processing, analytical platforms, and inconsistent biomarker thresholds. The review further evaluates the transition from biomarker discovery to clinical decision support, highlighting the need for prospective multicentre validation, standardised analytical procedures, external validation of computational models, and integration with molecular subtyping, circulating tumour DNA, imaging, and immune profiling. Rather than interpreting inflammation as a static prognostic variable, longitudinal inflammatory trajectories may provide earlier signals of biological treatment resistance and complement conventional measures of disease progression. Future research should establish clinically actionable inflammatory combinations and evaluate biomarker-guided anti-inflammatory strategies alongside standard therapies. Ultimately, integrating inflammatory phenotypes with tumour molecular characteristics may facilitate earlier recognition of resistance and more precise, dynamic, and equitable breast cancer management.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1918787"},"PeriodicalIF":4.0,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of personalised medicine in treating high-risk neuroblastoma in paediatric patients. 个性化药物在治疗高危神经母细胞瘤儿科患者中的作用。
IF 4
Oncology Reviews Pub Date : 2026-10-07 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1850627
Daniele Ammeti, Debora Curci, Martina Franzin, Marco Rabusin, Melania Eva Zanchetta, Antonella Fabretto
{"title":"The role of personalised medicine in treating high-risk neuroblastoma in paediatric patients.","authors":"Daniele Ammeti, Debora Curci, Martina Franzin, Marco Rabusin, Melania Eva Zanchetta, Antonella Fabretto","doi":"10.3389/or.2026.1850627","DOIUrl":"10.3389/or.2026.1850627","url":null,"abstract":"<p><p>Neuroblastoma (NB) is one of the most challenging paediatric malignancies, accounting for 15% of childhood cancer-related deaths. It is characterised by a high heterogeneity ranging from spontaneous regression to high frequency of metastatic disease at diagnosis. Although current treatment strategies, including chemotherapy, surgery and radiotherapy, have improved outcomes, recurrence often occurs in high-risk NB patients, thus affecting overall survival. In this context, personalised medicine is emerging as a promising approach taking advantage of predictive biomarkers to refine risk stratification and to predict treatment response, together with the development of innovative treatments for high-risk NB. This review summarises the landscape of biomarkers in NB, focusing on genomic, transcriptomic, proteomic, and metabolomic signatures associated with aggressive disease biology, therapeutic resistance, and clinical outcome. We highlight how improved patient stratification could help to identify actionable targets resulting in innovative therapeutic strategies. These include GD2-directed immunotherapy, CAR-T and CAR-NK cell approaches, and pathway-directed agents targeting mainly ALK, and MYCN-associated dependencies. Ultimately, the transition from standardised protocols to a systematic integration of multidimensional biomarker profiles with next-generation therapies promises to transform the clinical management of high-risk NB. Addressing the biological complexity of NB ensures more effective and less toxic interventions, paving the way for personalised therapeutic approaches aimed at preventing relapse in high-risk cases and significantly improving long-term survival.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1850627"},"PeriodicalIF":4.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149239020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood-based inflammatory biomarkers in ovarian cancer: addressing the challenge of early detection, metastasis, and prognostic stratification. 基于血液的卵巢癌炎症生物标志物:解决早期检测、转移和预后分层的挑战。
IF 4
Oncology Reviews Pub Date : 2026-10-07 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1914468
Emmanuel Ifeanyi Obeagu
{"title":"Blood-based inflammatory biomarkers in ovarian cancer: addressing the challenge of early detection, metastasis, and prognostic stratification.","authors":"Emmanuel Ifeanyi Obeagu","doi":"10.3389/or.2026.1914468","DOIUrl":"10.3389/or.2026.1914468","url":null,"abstract":"<p><p>Ovarian cancer remains a major cause of gynaecological cancer mortality, largely because early disease is frequently asymptomatic and reliable population-based screening remains unavailable. Systemic inflammation is increasingly recognised as an important component of ovarian cancer biology, linking tumour progression, immune dysregulation, angiogenesis, metastasis and treatment resistance. This narrative review critically evaluates blood-based inflammatory biomarkers, including C-reactive protein, interleukin-6, interleukin-8, tumour necrosis factor-α, fibrinogen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) and pan-immune-inflammation value (PIV), across early detection, metastatic assessment, treatment decision-making and prognostic stratification. Available evidence indicates that elevated inflammatory indices are consistently associated with advanced disease and adverse outcomes, although substantial heterogeneity exists in biomarker thresholds, populations, timing of measurement and analytical approaches. Recent evidence also suggests that preoperative NLR and SII may contribute to treatment selection, including neoadjuvant chemotherapy, although prognostic independence is not consistently demonstrated. Importantly, inflammatory biomarkers lack sufficient specificity for standalone ovarian cancer screening and should not replace CA-125, HE4, imaging or histopathological assessment. Their greatest clinical potential lies in multimarker models integrating systemic inflammatory, tumour-specific, molecular and clinical variables. Future research should prioritise prospective multicentre validation, standardised thresholds, longitudinal assessment and clinically interpretable prediction models to determine whether inflammatory profiling can advance precision risk stratification and treatment selection in ovarian cancer.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1914468"},"PeriodicalIF":4.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13684002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149239005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of oligometastatic disease in colorectal cancer: from molecular biology to multimodal strategies. 结直肠癌低转移性疾病的治疗:从分子生物学到多模式策略。
IF 4
Oncology Reviews Pub Date : 2026-10-05 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1932297
G Arrichiello, A Piccolo, F Carlino, E Franzese, A Ventriglia, M Annunziata, V Patanè, M De Siero, M D Bisceglia, M Orditura
{"title":"Treatment of oligometastatic disease in colorectal cancer: from molecular biology to multimodal strategies.","authors":"G Arrichiello, A Piccolo, F Carlino, E Franzese, A Ventriglia, M Annunziata, V Patanè, M De Siero, M D Bisceglia, M Orditura","doi":"10.3389/or.2026.1932297","DOIUrl":"10.3389/or.2026.1932297","url":null,"abstract":"<p><p>The management of oligometastatic colorectal cancer (OMD-CRC) has undergone a profound evolution, transforming what was once a uniformly fatal diagnosis into a clinical scenario in which long-term survival and even cure are attainable for a carefully selected subset of patients. This review provides a comprehensive synthesis of integrated, multidisciplinary strategies for OMD-CRC, with particular emphasis on hepatic and pulmonary metastases. We examine the biological foundations that differentiate oligometastatic from polymetastatic disease, including molecular subtypes that inform prognosis and therapeutic responsiveness. Local treatment modalities are critically evaluated, ranging from surgical metastasectomy-the standard of care in adequately selected patients-to minimally invasive approaches such as thermal ablation and Stereotactic Body Radiotherapy (SBRT). Recent randomized trials and prospective studies have suggested possible non-inferiority of these alternatives to surgery in selected contexts, thereby broadening the spectrum of curative-intent interventions. Equally pivotal is the integration of systemic therapy. We discuss optimal timing (neoadjuvant, adjuvant, perioperative) and regimen selection for both resectable and initially unresectable disease. The role of conversion therapy, combining intensive chemotherapy with targeted agents guided by molecular determinants such as RAS/BRAF mutational status and tumor sidedness, is highlighted as a cornerstone in expanding surgical eligibility. Looking ahead, emerging technologies-including radiomics and liquid biopsy approaches such as circulating tumor DNA (ctDNA)-hold promise for refining patient selection, detecting minimal residual disease, and further individualizing treatment pathways. The convergence of advanced local therapies, precision-guided systemic regimens, and novel biomarkers delineates the new frontier in optimizing outcomes for patients with OMD-CRC.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1932297"},"PeriodicalIF":4.0,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the immune enhancement effect of radiotherapy combined with NK cells on non-small cell lung cancer based on proteomics technology. 基于蛋白质组学技术探讨放疗联合NK细胞对非小细胞肺癌的免疫增强作用。
IF 4
Oncology Reviews Pub Date : 2026-10-01 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1853377
Cui Chang, Tang Youming, Lu Ying, Lei Ningning, Guo Chunhui, Wei Dekai, Liang Mei, Wu Qiyuan, Liu Gechen, Wu Fasheng, Chen Jibing
{"title":"Exploring the immune enhancement effect of radiotherapy combined with NK cells on non-small cell lung cancer based on proteomics technology.","authors":"Cui Chang, Tang Youming, Lu Ying, Lei Ningning, Guo Chunhui, Wei Dekai, Liang Mei, Wu Qiyuan, Liu Gechen, Wu Fasheng, Chen Jibing","doi":"10.3389/or.2026.1853377","DOIUrl":"10.3389/or.2026.1853377","url":null,"abstract":"<p><strong>Background: </strong>Although radiotherapy (RT) and natural killer (NK) cell-based therapy have shown promising potential in the treatment of non-small cell lung cancer (NSCLC), the therapeutic efficacy and safety of their combination remain to be fully elucidated. In this study, we evaluated the efficacy and safety of combined RT and NK cell therapy and performed preliminary proteomic profiling to characterize its potential effects on the tumor immune microenvironment (TIME), providing new insights and a theoretical and clinical basis for the development of NK cell-based therapeutic strategies for NSCLC.</p><p><strong>Methods: </strong>C57BL/6-derived subcutaneous Lewis lung carcinoma models were established to determine the minimal effective dose of both radiotherapy and adoptively transferred natural killer cells. Based on the MED-derived findings, the mice were further randomized into five experimental groups for therapeutic efficacy evaluation: the Control group, the RT group, the NK group, the combination therapy group (RN group), and the repeated combination therapy group (RN2 group). Tumour volume and body weight were monitored longitudinally. Differentially abundant proteins were interrogated by Gene Ontology enrichment and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analyses to systematically describe the synergistic antitumor efficacy of differentially expressed proteins.</p><p><strong>Results: </strong>Compared with RT or NK cell-based immunotherapy as monotherapies, the RN group exhibited markedly enhanced tumor growth inhibition, with no overt treatment-related toxicities observed. Following the second cycle of combined therapy, mice in the RN2 group displayed a more pronounced reduction in tumor growth rate with those in the single-cycle combination cohort; notably, no significant adverse events associated with the combined regimen were detected throughout the entire experimental duration. Proteomic profiling unraveled that RT disrupted the core regulatory networks governing intracellular DNA replication and repair processes in tumor cells in a therapy-specific manner, whereas NK cell immunotherapy potently and selectively activated the classical pathway of the host complement system.</p><p><strong>Conclusion: </strong>Collectively, RT and NK cell therapy demonstrate superior synergistic efficacy and no overt toxicity was observed, with repeated treatments further delaying tumor progression. Mechanistically, proteomics shows that RT disrupts DNA replication/repair networks, whereas NK cell therapy was associated with upregulation of multiple complement components, including those belonging to the classical and lectin pathways, suggesting a potential involvement of these pathways.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1853377"},"PeriodicalIF":4.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary pulmonary NUT carcinoma: pathological features, clinical diagnosis, treatment, and prognosis - An extended review. 原发性肺NUT癌:病理特征、临床诊断、治疗和预后综述。
IF 4
Oncology Reviews Pub Date : 2026-09-28 eCollection Date: 2026-01-01 DOI: 10.3389/or.2026.1967215
Shan Wu, Miao Zhang, Hui Wang
{"title":"Primary pulmonary NUT carcinoma: pathological features, clinical diagnosis, treatment, and prognosis - An extended review.","authors":"Shan Wu, Miao Zhang, Hui Wang","doi":"10.3389/or.2026.1967215","DOIUrl":"10.3389/or.2026.1967215","url":null,"abstract":"<p><p>NUT carcinoma is a rare and aggressive lung tumor driven by NUTM1 gene rearrangements. It accounts for less than 1% of all lung cancers, with fewer than 100 cases reported worldwide. The disease is often misdiagnosed due to non-specific symptoms and histological overlap with other tumors. This review provides an updated overview of its pathological features, clinical presentation, diagnosis, treatment, and prognosis, aiming to serve as a practical reference for clinicians and pathologists.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1967215"},"PeriodicalIF":4.0,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书